Telomir Pharmaceuticals
NASDAQ
•
[currency]
[price]
[tf_change]
[tf_text]
1D5D1M3M6MYTD1Y2Y
Today Open
[stock_day_open]
Day Range
[day_low]
-
[day_high]
Volume
[stock_day_vol]
Average Volume
[stock_avg_vol]
Market Cap
119051000
Year Range
[52w_low]
-
[52w_high]
Website
Website
https://telomirpharma.com/
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company dedicated to developing TELOMIR-1, a novel small molecule designed to elongate DNA's protective telomere caps. This approach aims to enhance the fidelity of DNA replication, potentially reversing cellular aging and addressing age-related inflammatory conditions such as hemochromatosis and osteoarthritis. By promoting telomere lengthening, TELOMIR-1 seeks to protect stem cells and sustain their self-renewal capabilities, offering a promising therapeutic intervention for age-associated diseases. Founded in 2021 and headquartered in Miami, Florida, Telomir Pharmaceuticals is committed to advancing longevity science through innovative treatments that target the fundamental mechanisms of aging.

Telomir Pharmaceuticals Feed

See the Feed
Telomir Pharmaceuticals Announces Breakthrough Results For Fully Reversing Oxidative Stress in Human Cell Lines
2025-01-28 7:51
  • Telomir Pharmaceuticals announced that its compound, Telomir-1, fully reversed oxidative stress caused by copper toxicity in human cell lines, a key factor in diseases like Alzheimer’s, AMD, cancer, and cardiovascular conditions
  • The drug showed effectiveness at low doses, suggesting a unique mechanism beyond traditional treatments, and is also being studied for antiviral applications, including bird flu, which has a 50% mortality rate globally
  • Telomir-1 is still in the preclinical stage and has not yet been tested in humans, but its potential to target oxidative stress offers a pathway to treat multiple high-impact diseases and viral outbreaks
    • TELO
    3.75
    %
    3.75
    %
    3.75
    %
    %
    %
    %
    %
    %
    %

    Telomir Pharmaceuticals in Trends

    More Trends
    No items found.

    Recent Telomir Pharmaceuticals Articles

    More Articles
    No items found.

    Discover the world's most disruptive early stage companies with 40,000+ investors.

    The markets and trends that matter, made simple.

    Join top talent at the world's most respected institutions, companies, and venture capital funds.
    Thank you! Your submission has been received!
    Oops! Something went wrong while submitting the form.